Effect of combined AURK and BCL2 inhibition on gene expression in double-hit lymphoma xenografted mice
RNA-seq (gene expression) · human · 27 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 27 samples: 27 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomasiScience · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE200410_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA824461. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 27 sample titles: 27 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM6032829 Vehicle Treated DoHH2 Tumor (biol rep 1)
- GSM6032830 Vehicle Treated DoHH2 Tumor (biol rep 2)
- GSM6032831 Vehicle Treated DoHH2 Tumor (biol rep 3)
- GSM6032832 Vehicle Treated DoHH2 Tumor (biol rep 4)
- GSM6032833 Vehicle Treated DoHH2 Tumor (biol rep 5)
- GSM6032834 Vehicle Treated DoHH2 Tumor (biol rep 6)
- GSM6032835 Vehicle Treated DoHH2 Tumor (biol rep 7)
- GSM6032836 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 1)
- GSM6032837 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 2)
- GSM6032838 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 3)
- GSM6032839 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 4)
- GSM6032840 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 5)
- GSM6032841 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 6)
- GSM6032842 MLN8237 (40 mg/kg) Treated DoHH2 Tumor (biol rep 7)
- GSM6032843 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 1)
- GSM6032844 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 2)
- GSM6032845 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 3)
- GSM6032846 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 4)
- GSM6032847 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 5)
- GSM6032848 Venetoclax (50 mg/kg) Treated DoHH2 Tumor (biol rep 6)
- GSM6032849 Combination Treated DoHH2 Tumor (biol rep 1)
- GSM6032850 Combination Treated DoHH2 Tumor (biol rep 2)
- GSM6032851 Combination Treated DoHH2 Tumor (biol rep 3)
- GSM6032852 Combination Treated DoHH2 Tumor (biol rep 4)
- GSM6032853 Combination Treated DoHH2 Tumor (biol rep 5)
- GSM6032854 Combination Treated DoHH2 Tumor (biol rep 6)
- GSM6032855 Combination Treated DoHH2 Tumor (biol rep 7)
- GSE303446 Beyond CD30 Targeting: Brentuximab Vedotin Triggers Immunogenic Cell Death and Antitumor Immunity in Mycosis Fungoides, Overcoming Resistance via BCL2 Inhibition 13 samples shares bcl2, inhibition
- GSE266219 Clinical and Immunological Responses to Combined JAK Inhibition and PD-1 immunotherapy for Lung Cancer Patients 79 samples shares inhibition, combined
- GSE309034 Combined BET Bromodomain and DNMT Inhibition Targets Lineage Plasticity in Prostate Cancer [BETi_DNMTi_human_RNAseq] 44 samples shares inhibition, combined
- GSE305560 TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia 18 samples shares inhibition, combined
- GSE324062 RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistance 61 samples shares bcl2
- GSE298581 Global gene expression response to PPARG inhibition in three urothelial cancer cell lines 48 samples shares inhibition
- GSE254732 Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects 215 samples shares inhibition
- GSE78220 mRNA expressions in pre-treatment melanomas undergoing anti-PD-1 checkpoint inhibition therapy 28 samples shares inhibition
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.